Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
NMT MEDICAL INC (NMTI)
|
Add to portfolio |
|
|
|
| Price: |
$0.01
| | Metrics |
| OS: |
13.2
|
M
| |
|
|
| Market cap: |
$132.3
|
k
| |
|
|
|
Net cash:
|
$3.4
|
M
| |
$0.26
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($7.6)
|
B
| |
|
|
|
EBIT
|
($7.5)
|
B
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 |
| Revenues | 13.2 | 17.9 | 26.8 | 28.2 | 23.9 | 21.5 | 23.0 | 25.0 |
| Revenue growth | -26.0% | -33.2% | -5.0% | 17.7% | 11.4% | -6.5% | -8.0% | 8.3% |
| Cost of goods sold | 5.5 | 6.0 | 5.4 | 5.9 | 5.5 | 4.5 | 5.3 | 6.6 |
| Gross profit | 7.7 | 11.9 | 21.3 | 22.2 | 18.4 | 16.9 | 17.7 | 18.4 |
| Gross margin | 58.4% | 66.6% | 79.8% | 78.9% | 77.1% | 79.0% | 76.9% | 73.5% |
| Sales and marketing | 5.5 | 8.8 | 9.1 | 8.7 | 6.3 | 5.5 | 5.6 | 5.4 |
| General and administrative | 6.8 | 8.6 | 8.0 | 8.7 | 8.0 | 6.0 | 5.5 | 5.5 |
| EBIT | -12.5 | -18.7 | -11.1 | 4.6 | -8.6 | -2.7 | -0.5 | 1.9 |
| EBIT margin | -94.5% | -104.3% | -41.6% | 16.2% | -36.1% | -12.4% | -2.0% | 7.5% |
| Pre-tax income | -12.4 | -18.0 | -9.2 | 6.4 | -7.9 | -2.0 | -1.0 | 9.6 |
| Income taxes | 0.0 | 0.1 | -0.1 | 0.5 | 0.0 | 0.0 | 0.1 | 3.4 |
| Tax rate | | | 1.3% | 7.9% | 0.0% | 0.0% | | 35.6% |
| Earnings from continuing ops | -12.4 | -18.1 | -9.1 | 5.9 | -7.9 | -2.0 | -1.1 | 6.2 |
| Earnings from discontinued ops | | | | | | -1.9 | | 4.9 |
| Net income | -12.4 | -18.1 | -9.1 | 5.9 | -7.8 | -3.9 | -1.1 | 11.1 |
| Net margin | -94.1% | -101.1% | -34.0% | 20.9% | -32.6% | -18.4% | -5.0% | 44.4% |
| |
| Diluted EPS | ($0.94) | ($1.39) | ($0.70) | $0.43 | ($0.64) | ($0.17) | ($0.10) | $0.51 |
| Shares outstanding (diluted) | 13.2 | 13.0 | 12.9 | 13.6 | 12.3 | 12.0 | 11.8 | 12.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|